AstraZeneca

Company Snapshot

Founded: 1999
Entity Type: Public
Employees: 94,300
Region: The Americas
Revenue: $54,073.0 Millions
Revenue Year: 2024
Segment: Oncology
Headquarter: Cambridge, U.K.
Key Geographics: The Americas, U.K., Rest of Europe, Asia, Africa, Australasia
Corporate Address: 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA, U.K. Tel: +44-(0)20-3749-5000 Web: www.astrazeneca.com

Company Overview

AstraZeneca is a U.K.-based biopharmaceutical company. The company operates in three segments and is focused on our chosen therapy areas: Oncology, Biopharmaceuticals, and rare diseases. The Biopharmaceuticals segment comprises therapeutic areas, including cardiovascular, renal, and metabolism (CVRM), respiratory and immunology (R&I), and vaccines and immune therapies (V&I). The company’s products are sold in over 125 countries.

The company’s R&D focuses on bispecific, inhaled fragments, ADCs, and cell-depleting monoclonal antibodies in antibody therapeutics.

The major brands are Forxiga or Farxiga, Ebymect, Edistride, Xigduo, Bydureon, Lynparza, Bydureon, Xigduo, Edistride, and Ebymect.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

AstraZeneca In Reports

Neuroprotective Agents: Therapeutic Applications and Global Markets

Our detailed report on neuroprotective agent market revenue ($ Million) for the base year of 2024 and estimated data for 2025 and the forecast period 2026 through 2030.

Monoclonal Antibodies for Oncology: Global Markets

According to BCC Research detailed report on Monoclonal Antibodies in Oncology Market with data from 2024, estimates from 2025, projections of compound annual growth rates through 2030 (forecast period 2025 – 2030). ...

Global Markets for Diabetes Therapeutics and Diagnostics

According to BCC Research detailed report on Diabetes Therapeutics and Diagnostics Markets with data from 2024, estimates from 2025, and projections of compound annual growth rates through 2030 (forecast period...

Company's Business Segments

  • Oncology : Cancer Care Africa, the Lung Ambition Alliance
  • Rare Disease : Hypophosphatasia (HPP), Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN), Wilson disease, and Rare cancers.
  • Other Medicines : Cardiovascular (CV), Renal & Metabolism, Respiratory & Immunology, and Vaccines & Immune Therapies.

Applications/End User Industries

  • Oncology
  • Cardiovascular
  • Renal
  • Metabolism
  • Respiratory and Immunology (R&I)
  • Vaccines and Immune Therapies (V&I)
  • Rare Disease
AI Sentiment